Published in Thromb Res on November 01, 1999
Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy. Vasc Health Risk Manag (2009) 0.79
Effects of different protein sources on plasminogen inhibitor-1 and factor VII coagulant activity added to a fat-rich meal in type 2 diabetes. Rev Diabet Stud (2010) 0.77
Visceral obesity and hemostatic profile in patients with type 2 diabetes: the effect of gender and metabolic compensation. Rev Diabet Stud (2004) 0.77
Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56
Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab (2000) 2.88
Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ (2001) 2.74
Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet (2001) 2.08
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab (2009) 2.04
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia (2007) 2.01
Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther (2000) 1.94
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab (2011) 1.87
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab (2010) 1.76
Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord (2004) 1.76
Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA (1990) 1.66
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab (2007) 1.61
Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab (2001) 1.58
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab (2007) 1.58
Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis (2001) 1.46
Relationship between alcohol intake, health and social status and cardiovascular risk factors in the Urban Paris-Ile-de-France Cohort: is the cardioprotective action of alcohol a myth? Eur J Clin Nutr (2010) 1.43
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab (2010) 1.43
Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med (2007) 1.43
[Iatrogenic hypertriglyceridemia]. Presse Med (1994) 1.39
Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation (1999) 1.31
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab (2007) 1.22
Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm Metab Res (2008) 1.19
Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res (2008) 1.19
A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab (2002) 1.18
Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab (1999) 1.18
Hypertriglyceridemic waist and 7.5-year prospective risk of cardiovascular disease in asymptomatic middle-aged men. Int J Obes (Lond) (2006) 1.15
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab (2009) 1.14
Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol (1996) 1.14
Secondary thyroidectomy in patients with prior thyroid surgery for benign disease: a study of 203 cases. Surgery (1999) 1.12
Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res (1988) 1.11
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab (2011) 1.11
Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol (2001) 1.10
[The Mediterranean lymphoma]. Presse Med (1970) 1.08
Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab (2001) 1.04
Sheehan's syndrome: differential diagnosis in the acute phase. J Intern Med (1998) 1.01
Committee report. Publication guidelines for heart rate studies in man. Psychophysiology (1981) 1.00
Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J (1998) 0.99
Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res (1993) 0.98
Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis (2012) 0.97
A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients. Metabolism (2002) 0.96
Risk factors for psychological distress following injury. Br J Clin Psychol (2006) 0.94
Effects of a low-calorie diet on resting metabolic rate and serum tri-iodothyronine levels in obese children. Eur J Pediatr (1999) 0.94
Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin (2010) 0.93
APOE: a potential marker of disease progression in ALS. Neurology (2002) 0.93
[Therapeutic correction of hereditary idiopathic hyperlipemia. Evaluation of a standard diet]. Nouv Presse Med (1973) 0.92
Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf) (2001) 0.92
Effects of stimulus intensity on autonomic responding: the problem of differentiating orienting and defense reflexes. Psychophysiology (1986) 0.91
Cysteine is a cardiovascular risk factor in hyperlipidemic patients. Atherosclerosis (1999) 0.91
Corrective therapy of atherogenic hyperlipemia. Acta Cardiol (1972) 0.91
[Further case of heavy alpha chain disease during abdominal lymphoma of the Mediterranean type with isolated tuberculosis of the mesenteric lymph nodes and pelvi-spondylitis]. Presse Med (1970) 0.91
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther (2007) 0.90
Relationship between thyroid hormones and plasma D-dimer levels. Thromb Haemost (1998) 0.89
The psychological burden of injury: an 18 month prospective cohort study. Emerg Med J (2002) 0.89
Variations in plasma soluble tumour necrosis factor receptors after diet-induced weight loss in obesity. Diabetes Obes Metab (2000) 0.89
Psychosocial factors, arousal and schizophrenic relapse. The psychophysiological data. Br J Psychiatry (1992) 0.89
Prevalence of lymphocytic infiltrate in 1400 pituitary adenomas. Endocr J (1998) 0.88
How do patients with type 2 diabetes perceive their disease? Insights from the French DIABASIS survey. Diabetes Metab (2009) 0.87
Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr Metab Cardiovasc Dis (2007) 0.87
[Frequency of hypothyroidism in a population of hyperlipidemic subjects]. Presse Med (1993) 0.87
Lessons from france: the cardiovascular prevention clinic in the la pitié-salpêtrière hospital in paris. Neth Heart J (2007) 0.87
Further characterization of the acetyl LDL (scavenger) receptor expressed by rabbit smooth muscle cells and fibroblasts. Arterioscler Thromb (1992) 0.87
[Nephrotic syndrome with extra-membranous glomerulitis associated with sarcoidosis]. J Urol Nephrol (Paris) (1968) 0.87
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab (2012) 0.86
17 alpha-hydroxylase deficiency syndrome associated with bilateral streak gonads and impaired development of Müllerian ducts derivatives. Report of a case. Acta Endocrinol (Copenh) (1982) 0.86
The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy. Atherosclerosis (1996) 0.86
Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP. Atherosclerosis (2004) 0.86
[Matrix metalloproteinases and atherosclerosis. Therapeutic aspects]. Ann Biol Clin (Paris) (2003) 0.85
Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris. Atherosclerosis (2000) 0.85
The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-IMilano. Atherosclerosis (1997) 0.85
Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab (2004) 0.85
Low free-thyroxine levels are a risk factor for subclinical atherosclerosis in euthyroid hyperlipidemic patients. J Cardiovasc Risk (1999) 0.84
A new male pseudo-hermaphroditism associated with hypertension due to a block of 17 -hydroxylation. J Clin Endocrinol Metab (1972) 0.84
Familial acromegaly: a specific clinical entity--further evidence from the genetic study of a three-generation family. Eur J Endocrinol (1995) 0.83
Apolipoprotein A-I (R151C)Paris is defective in activation of lecithin: cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux. J Mol Med (Berl) (1999) 0.83
Peroxisome proliferator activated receptor-gamma, leptin and tumor necrosis factor-alpha mRNA expression during very low calorie diet in subcutaneous adipose tissue in obese women. Diabetes Metab Res Rev (1999) 0.83
Physiological effects of downhill skiing at moderate altitude in untrained middle-aged men. Wilderness Environ Med (1996) 0.83
[Granular cell tumors. Rare tumors of the neurohypophysis]. Presse Med (1995) 0.82
Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy. AIDS (2001) 0.82
A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism (1992) 0.82
Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther (1996) 0.82
GLP-1: what is known, new and controversial in 2010? Diabetes Metab (2010) 0.82
Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism. J Endocrinol Invest (2005) 0.82
Cardiac and forearm plethysmographic responses to high intensity auditory stimulation. Biol Psychol (1978) 0.82
Serum levels of adhesion molecules ICAM-1 and VCAM-1 and tissue inhibitor of metalloproteinases, TIMP-1, are elevated in patients with autoimmune thyroid disorders: relevance to vascular inflammation. Nutr Metab Cardiovasc Dis (2010) 0.81
Education for people with progressive neurological conditions can have negative effects: evidence from a randomized controlled trial. Clin Rehabil (2004) 0.81